SCH772984

**SCH772984** is an investigational, highly selective small molecule inhibitor targeting the mitogen-activated protein kinases **ERK1** and **ERK2**. It acts as an ATP-competitive and partially non-competitive inhibitor, with additional allosteric properties that inhibit ERK activation/phosphorylation by MEK[1][5][9]. SCH772984 is notable for its dual mechanism of action: it inhibits both the catalytic activity of ERK1/2 and prevents their phosphorylation, thus more completely suppressing the MAPK pathway signaling compared to other ERK inhibitors that typically inhibit only kinase activity[1][3]. The compound is particularly effective at nanomolar concentrations in preclinical cancer models, including those with acquired resistance to BRAF and MEK inhibitors, especially in melanoma, pancreatic ductal adenocarcinoma, and other solid cancers featuring MAPK pathway activation[5][7][2]. SCH772984 was developed by Merck and has shown potency in multiple tumor models but suffers from poor bioavailability in vivo, limiting its applicability in clinical settings[1][3][7][5]. Mechanistically, SCH772984 engages a unique inhibitor binding pocket in ERK1/2, caused by an inactive conformation of the phosphate-binding loop and a shift of the α-C helix[1][9].

Other names

SCH772984SCH-772984SCH 772984PD017002PD-017002PD 017002